Treatment with everolimus is known to prolong progression-free survival in patients with renal cell carcinoma resistant against tyrosine-kinase inhibitor therapy.
The side effects must be known for more effective use of this drug. Information of side effects was collected from a randomized controlled study, the early post-marketing phase vigilance and from our own experience. Interstitial lung disease (ILD) was a potentially severe side effect. Incidence of ILD was relatively large compared with that of other target therapy agents. Infections, thrombocytopenia, stomatitis and others were experienced as other side effects. However, there were few uncontrollable side effects. Management of side effects of everolimus can be improved by obtaining sufficient knowledge.
Written by:
Mikami K, Hongo F, Miki T. Are you the author?
The Department of Urology, Kyoto Prefectural University of Medicine Graduate School of Medical Science.
Reference: Hinyokika Kiyo. 2012 Nov;58(11):647-50.
PubMed Abstract
PMID: 23254794
Article in Japanese.
UroToday.com Renal Cancer Section
